Through the activation of the butyrate-GPR109A signaling axis, this combination therapy effectively inhibits NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome activation and reduces renal IL-18 secretion, providing additional renoprotection in DN (107, 113). The gene discussed is NLRP3; the disease is liver dysplastic nodule.